Clinical Trial: Mixed Chimeric Transplantation for Primary Amyloidosis
Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional
Official Title: Mixed Chimeric Transplantation for Primary Amyloidosis
Brief Summary: To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.
Detailed Summary:
Sponsor: Stanford University
Current Primary Outcome: Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Toxicity of therapy
- Changes in marrow and serum abnormalities
- Improvement in end-organ function.
Original Secondary Outcome:
- - Toxicity of therapy
- - Changes in marrow and serum abnormalities
- - Improvement in end-organ function.
Information By: Stanford University
Dates:
Date Received: September 13, 2005
Date Started: December 2000
Date Completion: September 2006
Last Updated: October 5, 2007
Last Verified: October 2007